gemcitabine has been researched along with Angioblastic Meningioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higa, N; Hirano, H; Kitanaka, C; Okada, M; Sanomachi, T; Seino, S; Sonoda, Y; Sugai, A; Suzuki, S; Takajo, T; Togashi, K; Uchida, H; Yamada, Y; Yamamoto, M; Yonezawa, H; Yoshimoto, K | 1 |
| Beddy, P; Collins, IM; O'Byrne, KJ | 1 |
2 other study(ies) available for gemcitabine and Angioblastic Meningioma
| Article | Year |
|---|---|
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Meningeal Neoplasms; Meningioma; Pancreatic Neoplasms | 2021 |
Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulins, Intravenous; Incidental Findings; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Staging; Receptor, IGF Type 1; Tomography, X-Ray Computed; Treatment Outcome | 2010 |